VG Life Sciences Provides Update on Phase I Advanced Stage Solid Tumor Cancer Study

VG Life Sciences (OTC: VGLS ) announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors. This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health